SOPHiA GENETICS chair sells 28,500 shares via plan

SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported two non-derivative stock sales of Ordinary Shares pursuant to a duly adopted Rule 10b5-1(c) trading plan.

Rhea-AI Filing Summary

SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported two non-derivative stock sales of Ordinary Shares pursuant to a duly adopted Rule 10b5-1(c) trading plan. On August 7, 2026, he sold 20,000 shares at a weighted average price of $7.227, in multiple trades between $7.20 and $7.27. On August 10, 2026, he sold 8,500 shares at a weighted average price of $7.6081, in multiple trades between $7.50 and $7.80. Post-transaction share holdings are not specified in this filing.

Insider Trade Summary 10b5-1

Net Seller: 28,500 shares

Net Sell 2 txns

Insider Camblong Jurgi

Role Executive Chairman

Sold 28,500 shs ($209K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1, F3	8,500	$7.6081	$65K
Sale	Ordinary Shares F1, F2	20,000	$7.227	$145K

Holdings After Transaction: Ordinary Shares — 3,444,322 shares (Direct)

Footnotes (3)

1. F1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.20 to $7.27, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.50 to $7.80, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold 2026-08-07: 20,000 shares Price range 2026-08-07: $7.20 to $7.27 Shares sold 2026-08-10: 8,500 shares +2 more

5 metrics

Shares sold 2026-08-07 20,000 shares Ordinary Shares sold by Jurgi Camblong at weighted average $7.227

Price range 2026-08-07 $7.20 to $7.27 Multiple transactions underlying the $7.227 weighted average price

Shares sold 2026-08-10 8,500 shares Ordinary Shares sold by Jurgi Camblong at weighted average $7.6081

Price range 2026-08-10 $7.50 to $7.80 Multiple transactions underlying the $7.6081 weighted average price

Total shares sold 28,500 shares Combined Ordinary Shares sold across both reported transactions

Key Terms

Rule 10b5-1(c), weighted average price, Ordinary Shares

3 terms

Rule 10b5-1(c) regulatory

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Ordinary Shares financial

"security_title": "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did SOPH Executive Chairman Jurgi Camblong report?

Jurgi Camblong reported two sales totaling 28,500 Ordinary Shares of SOPHiA GENETICS SA. The trades occurred on August 7, 2026 and August 10, 2026 at weighted average prices of $7.227 and $7.6081, respectively.

How many SOPH shares did Jurgi Camblong sell on August 7, 2026 and at what price?

On August 7, 2026, Jurgi Camblong sold 20,000 Ordinary Shares of SOPHiA GENETICS SA at a weighted average price of $7.227, with individual trades executed between $7.20 and $7.27 per share.

What were the details of Jurgi Camblong’s August 10, 2026 SOPH share sale?

On August 10, 2026, Jurgi Camblong sold 8,500 Ordinary Shares at a weighted average price of $7.6081. Individual transactions occurred in a range from $7.50 to $7.80 per share, according to the Form 4 footnote.

Were Jurgi Camblong’s SOPH share sales made under a Rule 10b5-1 trading plan?

Yes. A footnote states the transactions were made pursuant to a duly adopted trading plan under Rule 10b5-1(c), indicating the sales were pre-arranged under that plan rather than discretionary at the time of execution.

Does the Form 4 disclose Jurgi Camblong’s SOPH shareholdings after these sales?

The Form 4 does not state the total shares held after the transactions. The reported data focuses on the 20,000 and 8,500 shares sold, with no post-transaction ownership figure provided for Camblong.

What is the total number of SOPH shares sold by Jurgi Camblong in this Form 4?

Across both reported transactions, Jurgi Camblong sold 28,500 Ordinary Shares of SOPHiA GENETICS SA. This includes 20,000 shares at $7.227 on August 7, 2026 and 8,500 shares at $7.6081 on August 10, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/10/2026 - 05:14 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Camblong Jurgi

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/07/2026		S		20,000(1)	D	$7.227(2)	3,452,822	D
Ordinary Shares	08/10/2026		S		8,500(1)	D	$7.6081(3)	3,444,322	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.20 to $7.27, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.50 to $7.80, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in- Fact for Jurgi Camblong	08/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)